Robert Weiss
Internal Medicine · Bala Cynwyd, PANPI 1083777403
Payments from drug & device makers
Across 202 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$840
- Kowa Pharmaceuticals America, Inc.$610
- Amgen$490
- Idorsia Pharmaceuticals US Inc$485
- AbbVie$452
- Medtronic$106
- plus $862 from 20 others
What the payments were for
- Food & beverage$3,845100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 41 | $840 |
| Kowa Pharmaceuticals America, Inc. | 52 | $610 |
| Amgen | 13 | $490 |
| Idorsia Pharmaceuticals US Inc | 17 | $485 |
| AbbVie(2 entities) | 31 | $452 |
| Medtronic | 1 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $95 |
| Avanir Pharmaceuticals, Inc. | 5 | $88 |
| Pfizer | 5 | $88 |
| Astellas Pharma US Inc | 5 | $84 |
| Lilly USA, LLC | 5 | $80 |
| Optinose US, Inc. | 3 | $71 |
| Johnson & Johnson | 3 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Stryker | 1 | $43 |
| Boehringer Ingelheim | 1 | $23 |
| Boston Scientific | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$241
- Repatha$237
- QUVIVIQ$115
- Mosaic$106
How this compares
$3,845 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $90,010 |
| MounjaroTirzepatide | 59 | $77,499 |
| OzempicSemaglutide | 54 | $50,290 |
| MyrbetriqMirabegron | 46 | $36,047 |
| JardianceEmpagliflozin | 38 | $34,482 |
| RybelsusSemaglutide | 18 | $29,131 |
| Praluent PenAlirocumab | 43 | $22,160 |
| XareltoRivaroxaban | 12 | $20,159 |
| ValiumDiazepam | 12 | $17,621 |
| Repatha SureclickEvolocumab | 20 | $16,347 |
| OmnitropeSomatropin | 13 | $14,833 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $12,394 |
| TrulancePlecanatide | 12 | $6,739 |
| GemtesaVibegron | 12 | $5,480 |
| SynthroidLevothyroxine Sodium | 49 | $4,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $90,01095 claims |
| Novo NordiskOzempic, Rybelsus | $17 | $79,42172 claims |
| Lilly USA, LLCMounjaro | $80 | $77,49959 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $36,04746 claims |
| Boehringer IngelheimJardiance | $23 | $34,48238 claims |
| Johnson & JohnsonXarelto | $67 | $20,15912 claims |
| GSKTrelegy Ellipta | $840 | $12,39421 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $95 | $6,73912 claims |
| AbbVieSynthroid | $452 | $4,75949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Bala Cynwyd
- Mohammed KidwaiBala Cynwyd$894K
- Janine KyrillosBala Cynwyd$192K
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.